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Pelvic organ prolapse aﬀ ects between 5% and 10% 
of women, and is strongly associated with increasing 
age, as shown by its prevalence of 40% in women 
older than 50 years.1 The disorder is one of the most 
common indications for gynaecological surgery in older 
women, and the estimated lifetime cumulative risk of 
surgery is 7–11%.2 In addition to the surgical procedures 
available for prolapse, conservative treatments include 
intravaginal pessaries, avoidance of activities that 
increase pressure on the pelvic ﬂ oor, weight loss, and 
pelvic ﬂ oor muscle training.
Pelvic ﬂ oor muscle training is an established treatment 
for some pelvic ﬂ oor disorders, including urinary and 
faecal incontinence. Such training is often combined with 
other behavioural approaches, such as urge suppression 
strategies, and can improve urinary urgency, frequency,3 
and nocturia.4 In fact, the International Consultation on 
Incontinence recommends pelvic ﬂ oor muscle training 
as the ﬁ rst-line treatment for stress, urge, or mixed 
incontinence in women of all ages.5 The 2011 American 
Urological Association guideline for diagnosis and 
treatment of overactive bladder in adults recommends 
that behavioural treatments, including pelvic ﬂ oor muscle 
training, be the ﬁ rst treatments oﬀ ered to all women, 
and men, with overactive bladder.6 Although pelvic ﬂ oor 
muscle training is used clinically to treat prolapse, little 
empirical evidence is available for its eﬀ ectiveness.7,8
In The Lancet, Suzanne Hagen and colleagues9 report 
results from their Pelvic Organ Prolapse PhysiotherapY 
(POPPY) trial, a 25-site, randomised controlled trial 
comparing one-to-one individualised pelvic ﬂ oor 
muscle training with a lifestyle advice leaﬂ et (control) in 
women with symptomatic stage I, II, or III prolapse, as 
conﬁ rmed by objective assessment. The intervention was 
delivered to newly diagnosed women by women’s health 
physiotherapists in ﬁ ve in-person visits over 16 weeks. 
Notably, the intervention was not limited to daily pelvic 
ﬂ oor muscle exercise. Women were taught to precontract 
pelvic ﬂ oor muscles during activities that increase intra-
abdominal pressure. Thus, in addition to the possible 
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heterogeneity and susceptibility across diﬀ erent risk 
groups and regions.
Despite major improvements in air quality in the past 
50 years, the data from Beelen and colleagues’ report 
draw attention to the continuing eﬀ ects of air pollution 
on health. These data, along with the ﬁ ndings from 
other large cohort studies, suggest that further public 
and environmental health policy interventions are 
necessary and have the potential to reduce morbidity 
and mortality across Europe. Movement towards more 
stringent guidelines, as recommended by WHO, should 
be an urgent priority.
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improvement in structural support at rest,10 treatment 
involved changes in muscle function, requiring women to 
be more vigilant and intentional in their daily activities.
Women who received pelvic ﬂ oor muscle training 
reported fewer prolapse symptoms (deﬁ ned as a 
signiﬁ cantly greater reduction in the pelvic organ prolapse 
symptom score [POP-SS]) than those in the control group, 
at both 6 months (between-group diﬀ erence in change 
from baseline 2·84, 95% CI 2·05–3·63) and 12 months, the 
trial’s primary endpoint (1·52, 0·42–2·59), after treatment. 
One of the challenges in interpretation of these ﬁ ndings is 
in understanding the meaning for patients of a 1·5-point 
diﬀ erence in symptom scores. The POP-SS is a validated 
method consisting of seven items addressing frequency 
of prolapse symptoms and yielding a total score between 
0 and 28. Although the eﬀ ect size might not seem large, 
it exceeds the minimally important change established 
for this method,11 showing its importance to patients. 
Furthermore, signiﬁ cant outcomes were shown for 
several secondary endpoints. For example, more women 
in the intervention group than the control group reported 
that their prolapse was ‘better’ at both 6 months (52% 
vs 17%) and 12 months (57% vs 45%), and a smaller 
proportion had sought further treatment by 12 months 
(24% vs 50%), showing less residual symptom burden.
Hagen and colleagues’ ﬁ ndings would have been more 
compelling had the objective measures, based on the 
pelvic organ prolapse quantiﬁ cation (POP-Q) system, 
shown signiﬁ cant treatment eﬀ ects. More women in the 
intervention group had improvement in prolapse stage 
at 6 months but this fell short of statistical signiﬁ cance, 
possibly because the trial was not powered to detect 
diﬀ erences in this measure. The intervention tested in 
the trial could be accommodated by the UK National 
Health Service. A more intensive programme of pelvic 
ﬂ oor muscle training might achieve enough connective 
tissue change to be detected in the POP-Q. Nevertheless, 
the POP-Q results do not diminish the importance of 
the primary ﬁ ndings, because symptom severity drives 
treatment seeking and is not highly correlated with 
prolapse stage.12,13
In interpretation of the ﬁ ndings, we should also 
consider the within-group variability in outcomes. In 
the pelvic ﬂ oor muscle training group, 57% of women 
reported that they were better, leaving 43% who said 
they were worse or the same. This shows that there 
are subgroups of responders and non-responders. 
Identiﬁ cation of the characteristics of these groups to 
enable selection of responders would be ideal, but is 
beyond present knowledge. In view of the safety and 
reasonable cost of the intervention, a rational approach 
would be to oﬀ er a trial of pelvic ﬂ oor muscle training to 
any woman with stage I–III prolapse who is motivated to 
engage in the treatment.
Historically, behavioural and physical treatments 
have been criticised for having inadequate durability. 
As with so many other studies, the magnitude of the 
treatment eﬀ ect in Hagen and colleagues’ study seems 
to diminish between 6–12 months. This decrease should 
not necessarily be attributed to waning eﬀ ectiveness 
of the muscle training itself. In interpretation of these 
ﬁ ndings, we should consider that the control group 
continued to improve over time, decreasing the gap 
between the groups, most likely because half of these 
women sought prolapse treatment outside the trial. Also 
noteworthy is that only 66% of participants completed 
the 12 month assessment, suggesting the possibility 
of selective attrition. Finally, although this trial reports 
good adherence (78%) at 12 months, the ﬁ ndings are a 
reminder of the diﬃ  culties in maintenance of the eﬀ ects of 
a behavioural intervention over time. Increased attention 
should be given to the development of interventions that 
improve adherence, helping women sustain their exercise 
regimen and behavioural changes long term.
POPPY makes an important contribution by 
strengthening the evidence base for pelvic ﬂ oor muscle 
training in women with prolapse. In addition to the 
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Melioidosis, dubbed the Vietnamese time bomb1 after 
reports of lengthy disease latency in war veterans, is 
caused by Burkholderia pseudomallei and manifests 
as acute, subacute, or chronic disease. Bacteraemic 
disease especially when associated with pneumonia 
is the most lethal form, especially if associated with 
septic shock, but infection with or without abscess 
formation can occur in any organ system. Although 
most presentations occur soon after exposure, the 
organism’s ability to evade host immune mechanisms 
and to survive and multiply in phagocytes2 gives rise to 
latency—latency of up to 62 years has been reported.3 
Seroprevalence rates vary widely but are highest in 
northeast Thailand, where most children show evidence 
of exposure.4 It remains unclear how many of those 
with serological evidence of exposure harbour latent 
B pseudomallei with the potential for subsequent 
activation. Several risk factors cause some people to 
have an increased risk of melioidosis, with diabetes 
being the most common.5
For those with culture-conﬁ rmed melioidosis, treat-
ment recommendations include an initial intensive 
intravenous course of at least 10 days with ceftazidime 
or a carbapenem.5 This course is followed by a so-called 
oral eradication phase of at least 3 months. The initial 
clinical response might indicate a need to modify the 
duration of the intensive phase, but the optimum 
antibiotic regimen and duration for eradication are 
uncertain. Recurrent melioidosis was noted in 13% 
of patients treated in Australia,6 but its prevalence 
has fallen over the past decade, possibly attributed to 
improved compliance, choice, and dosing of antibiotic 
regimens.7 Higher rates of recurrence in Thailand have 
been associated with inadequate duration of treatment.8
In The Lancet, Ploenchan Chetchotisakd and 
colleagues present ﬁ ndings from the MERTH trial,9 in 
which they enrolled 626 patients with melioidosis, 
randomly allocating them to receive trimethoprim-
sulfamethoxazole alone (the recommended regimen 
in Australia) or trimethoprim-sulfamethoxazole 
 Melioidosis: reﬁ ning management of a tropical time bomb
eﬀ ectiveness of muscle training, the trial also shows the 
potential for prevention of prolapse symptoms through 
lifelong attention to pelvic ﬂ oor muscle exercise, and 
possibly intentional use of muscles to protect the pelvic 
ﬂ oor during physical strain, such as that inﬂ icted by 
heavy lifting. The results of this trial should encourage 
clinicians to refer women to physiotherapists, and to 
other health-care professionals who can implement 
behavioural and physical therapies for prolapse in a 
range of health-care settings.
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